"Mood" is defined as a ubiquitous and sustained feeling or emotion that dominates a person’s behavior and affects his perception. Mood disorders also known as affective disorders include depressive disorder, bipolar disorder, and other disorders.
Hippocrates described mania and melancholia as mental disorders but it was Jules Farley in 1854, who first described folie circulaire or alternating cycle of mania and depression. In 1899 Emil Kraepelin outlined manic-depressive psychosis using most of the current criteria and arrived at the diagnosis of bipolar 1 disorder.
The bipolar affective disorder is a chronic and complex disorder of mood that is characterized by a combination of manic (bipolar mania), hypomanic and depressive (bipolar depression) episodes, with substantial subsyndromal symptoms that commonly present between major mood episodes. It is one of the top causes of worldwide disability. Bipolar 1 disorder has been frequently associated with serious medical and psychiatric comorbidity, early mortality, high levels of functional disability and compromised quality of life. The necessary feature of bipolar 1 disorder involves the occurrence of at least one lifetime manic episode, although depressive episodes are common. Bipolar 2 disorder needs the occurrence of at least one hypomanic episode and one major depressive episode.
According to the DSM V, the only requirement for the diagnosis of bipolar 1 disorder is at least one lifetime episode of mania. Depression may or may not be present.
The bipolar affective disorder can be caused by a variety of factors. Some of those are listed below:
Genetic Factors: The risk of bipolar disorder is 10-25% when one parent has a mood disorder. Twin studies have shown 70-90% concordance rates in monozygotic twins. Chromosome 18q and 22q have the strongest evidence for linkage to bipolar disorder. Bipolar 1 disorder has the highest genetic link of all psychiatric disorders.
Structural and Functional Imaging: Abnormal hyperintensities in the subcortical regions, especially thalamus, basal ganglia, and the periventricular area in bipolar disorder, indicated recurrent episodes and show neurodegeneration. Patients with severe depression or a family history of mood disorder show increased glucose metabolism in the limbic region with decreased metabolism of the anterior cerebral cortex.
Biogenic Amines: Dopamine is decreased in depression and increased in mania.
Second Messengers: G proteins or guanine binding nucleoproteins are targets for mood stabilizers. They interact with membrane receptors and form second messengers like cyclic adenosine monophosphate (cAMP ) and cyclic guanosine monophosphate (cGMP). Second messengers regulate neuronal membrane channels.
Hormone Regulation Imbalance: Adrenocortical hyperactivity is observed in mania. Chronic stress decreases neurokinin brain-derived neurotrophic factor (BDNF), which impairs neurogenesis and neuroplasticity. The growth hormone is released after stimulation from dopamine and norepinephrine and its release inhibited by somatostatin. Increased CSF somatostatin levels are observed in mania.
Immunological Factors: Chronic elevation of cytokines and interleukins associated with clinical severity.
A significant life stressor can lead to neuronal changes such as neurotransmitter levels, synaptic signaling alterations, as well as neuronal loss. This is implicated in the first episode of the mood disorder, as well as the recurrence of subsequent episodes.
Histrionic, obsessive-compulsive, and borderline personalities are more prone to depression. Those with cyclothymia or dysthymia are prone to bipolar 1 disorder or depression.
In the general population, the lifetime prevalence of bipolar affective disorder is around 1% for bipolar type 1. A large cross-sectional survey of 11 countries noted that the overall lifetime prevalence of bipolar spectrum disorders was 2.4%, with a prevalence of 0.6% for bipolar type 1 and 0.4% for bipolar type 2. Prevalence of Hypomania is about 2.6-7.8%, and that of Cyclothymia is about 0.5 to 6.3%.
Most studies suggest that bipolar 1 disorder has an equal prevalence in both men and women, while others have recognized a higher prevalence of manic episodes and bipolar type 1 in males and higher rates of bipolar type 2 in females. Overall, the evidence is not very strong to move from the point of view that bipolar appears to have an approximately equal distribution across sex and ethnicity.
The mean age of onset for bipolar is in the early twenties, although findings vary between 20–30 years. A bimodal distribution has also been suggested, as noted by a large population-based cohort study, which found peaks in the age of onset at 15 to 24 years and at 45 to 54 years. It is noteworthy that the age of onset is very difficult to estimate define accurately for bipolar, as most of the time, there are long periods of untreated illness when symptoms can be present without individuals accessing services.
Patients with mood disorders are at very high risk of death by suicide. The incidence of death by suicide among patients with a diagnosis of bipolar affective disorder is high and proposed to be 20 times more than in the general population, notably when bipolar disorder is untreated. About one in three to one in two patients with bipolar disorder attempt suicide at least once in the course of their lifetime, and approximately 15–20% of attempts are successful.
The bipolar affective disorder is considered one of the most heritable psychiatric disorders; however, a multifactorial model in which gene and environment interact is presently thought to be responsible. Many alleles of small effect, which somewhat overlap with schizophrenia (e.g., CACNA1C, TENM4, and NCAN) and are described in genome-wide association studies, add to the polygenic risk of bipolar disorder.
Neurotrophic molecules, such as brain-derived neurotrophic factor, have an important role in signaling pathways of dendritic sprouting and neural plasticity. Dendritic spine loss has been observed in the post-mortem brain tissue of patients with bipolar affective disorder. Other pathways that can affect neuronal interconnectivity are also being studied, which include dysfunction of mitochondria and endoplasmic reticulum stress, neuroinflammation, apoptosis, oxidation and epigenetic changes, particularly histone and DNA methylation.
A patient with mania is excited and can appear grossly psychotic. They often are garishly dressed, excessively friendly or talkative, and appear to be unnaturally "happy". Hand-wringing and excessive pacing may be present.
Mood and Affect
Elevated mood with unusually bright affect in mania. The patient may be euphoric or irritable and may have a labile mood during mania. Depressed mood, limited or flat affect in depression.
A manic patient may be very talkative. However, there is a slow and soft speech in depression.
Mood congruent delusion may be present in depression example- failure, guilt. Grandiose delusion may be present in mania especially those referring to power or wealth. A manic patient can also have mood-incongruent delusions.
Patients with mania show elevated confidence, self-aggrandization, easy distractibility, and flow of ideas or racing thoughts. A depressed patient usually has negative thoughts and negative ruminations.
Sensorium and Cognition
Usually oriented to person, place, and time. Depressed patients may have some impairment in cognition and memory. Manic patients may have grossly intact memory and cognition. Sometimes orientation is impaired and is called manic delirium.
Extremely depressed patients lack the energy or motivation to commit suicide and there is an increased risk of suicidal attempts when they regain energy. Manic patients are threatening and assaultive.
Judgment and Insight
Impaired judgment is the distinctive feature of mania along with limited insight. Depressed patients often overemphasize their symptoms.
Manic patients are usually unreliable in the information they provide. Depressed patients overemphasize negative symptoms and treatment failure.
Correct diagnosis of the bipolar affective disorder is facilitated, to a large degree, by a focused clinical psychiatric assessment with the patient and their relatives, to recognize the longitudinal course of the disorder.
Most laboratory results are normal in bipolar affective disorders. It is important to rule out substance-induced mood disorder by ordering a urine drug screen and serum ethyl alcohol levels when applicable. Thyroid-stimulating hormone levels should be checked to rule out mood change due to hypothyroid or hyperthyroid state.
If the patient has already been diagnosed with bipolar affective disorder and has been on mood stabilizers for treatment, consider serum valproic acid levels, serum lamotrigine levels, or serum carbamazepine levels to determine therapeutic levels in order to titrate medication.
Mania can be diagnosed as:
A distinct period of persistent and abnormally elevated, expansive, or irritable mood with the abnormal, persistent, increased goal-directed activity which lasts more than one week and is present most of the day almost every day.
The mood disturbance causes social, occupational, and functional impairment with or without psychosis. There can also be a perceivable threat to self or others.
The presence of three or more of the following symptoms during the episode, which is not usual behavior:
Grandiosity or elevated self-worth eg., unrealistic belief that one is powerful or influential
Decreased need for sleep
Pressured speech, talkative, fast speech
Flight of ideas or complain of racing thoughts
Distractibility and inability to focus easily jumps from one topic to another
Increased goal-directed activity or psychomotor agitation, appears restless, constant moving or tapping of feet
Engagement in activities which will have undesirable consequences, engaging in high-risk behavior
Hypomania is characteristic of bipolar 1 but not required for diagnosis. It can be diagnosed as:
A distinct period of persistent and abnormally elevated, expansive, or irritable mood with an abnormal, persistent, increased goal-directed activity which lasts at least four days and is present most of the day almost every day.
Three or more symptoms of mania present.
Mood symptoms are perceivable by others.
No significant occupation or social functioning impairment and no psychosis.
Hypomanic symptoms are independent of the action of medication, illicit substance, or another medical condition. Hypomania can be seen after antidepressant therapy initiation as well as after electroconvulsive therapy but when hypomania is related to bipolar disorder, the symptoms are present for a longer time and are more pronounced.
Major depressive episodes are present in bipolar 1 disorder but not required for diagnosis. Five or more symptoms listed below present for more than two weeks which cause impairment in social and occupational functioning:
A subjective or objective depressed mood eg., feeling empty, hopeless, sad, low, or observation by others that one is tearful
Anhedonia or loss of interest in pleasurable activities
Change in weight, loss, or gain, of 5% body weight within one month
Change in sleep, insomnia, or hypersomnolence
Psychomotor agitation or retardation (mostly objective)
Guilt or worthlessness
Decreased concentration, inability to focus
Suicidal ideation with or without plan or thoughts of dying
The symptoms are not secondary to medication, illicit drugs, or other medical conditions.
Bipolar 2 disorder is also known as recurrent major depression with hypomania. The DSM V criteria for the diagnosis of bipolar 2 disorder is one or more major depressive episodes and at least one episode of hypomania. If mania is present, then the diagnosis is bipolar 1 disorder.
When diagnosing bipolar disorder, it must be specified if the disorder is:
The primary step in the management of bipolar affective disorder is to confirm the diagnosis of mania or hypomania and define the patient’s mood state because the treatment approach differs significantly for hypomania, mania, depression, and euthymia. Various factors can affect pharmacological and psychological approaches; these comprise medical and psychiatric comorbidities, past or current treatments, treatment response or adverse effects in patients and relatives, and the patient’s inclination to be treated.
In acute management, the primary goals are to ensure the safety of patients and nearby people, achieve clinical and functional stabilization with the least possible adverse effects. Additionally, engagement in treatment and development of a therapeutic alliance is important in any chronic disorder that requires long-term adherence, and this collaboration is especially true during the first episode.
Mood stabilizers and antipsychotics are the foundation of acute management of bipolar mania and depression. Mood stabilizers are the main pharmacological agents for the treatment of bipolar affective disorder, particularly in the acute phase of mania. Lithium is the gold standard for the treatment of bipolar disorder as long term use has demonstrated a reduction in suicide risk. 50%-70% of patients treated with lithium show a reduction in mania. Lithium has a narrow therapeutic index, and serum lithium levels should be monitored. Carbamazepine and valproic acid are anticonvulsants that have a mood-stabilizing effect and are also utilized in many cases for acute manic episodes. Second generation or atypical antipsychotics like olanzapine, quetiapine, risperidone, ziprasidone are indicated as monotherapy or in combination with a mood stabilizer. Combination therapy using a mood stabilizer and an antipsychotic has shown a greater response than treatment with either single agent. Of note, lurasidone is considered highly effective for depressive symptoms in bipolar affective disorder.
Notably, evidence for the use of antidepressants to treat depression is not well understood, and these drugs should never be used as monotherapy in bipolar 1 disorder. It has also been postulated that antidepressants can trigger a manic episode in patients with bipolar affective disorder.
Electroconvulsive therapy is extremely effective for treatment-resistant acute mood episodes like refractory depression or acute life-threatening mania, predominantly in patients with psychotic or catatonic features, and it is the best treatment for mania in a pregnant female.
In long-term management, the main objectives are to prevent relapse of episodes and ensure functionality while optimizing treatment. Pharmacotherapy, usually consisting of a mood stabilizer alone or in combination with antipsychotic or antidepressant plus customized psychosocial interventions in euthymia, can reduce the chance of relapse, enhance treatment adherence, and decrease the number and duration of hospital admissions. Psychoeducation has been shown to have significant prophylactic effects in individuals with bipolar disorder. Other valuable treatments for patients include cognitive behavioral therapy, interpersonal and social rhythm therapy, and family-focused therapy. Functional remediation has also shown efficacy in enhancing functioning ability in patients with bipolar 1 and bipolar 2 disorder with psychosocial functional deficits.
Bipolar depression often persists longer, and it is very challenging to treat, needing a different approach from that used in unipolar depression. The broad consensus is that quetiapine, olanzapine, lamotrigine, lurasidone, and antidepressants have some efficacy but show varying tolerability.
Major Depressive Disorder: can also be associated with hypomania or mania, but these are of shorter duration and have fewer manic or hypomanic symptoms than bipolar disorder.
Generalized Anxiety Disorder: panic disorder, posttraumatic stress disorder, and other anxiety disorders can be comorbid disorders with bipolar disorders.
Substance-induced Bipolar Disorder: can be due to medication or chemical dependency and can present as mania. Bipolar 1 disorder should be diagnosed if manic symptoms are present without the influence of medication or chemical dependency.
Attention-deficit/hyperactivity disorder: can present with similar symptoms as mania in children and adolescents.
Medical comorbidities are quite prevalent in patients with bipolar disorder because of the adverse effects of treatment with mood stabilizers, anticonvulsants, antipsychotics, genetic vulnerability, and lifestyle factors (poor diet, lack of exercise, alcohol use, smoking). Keeping in mind the burden of these comorbidities and adverse effects of pharmacotherapy, regular monitoring of weight, glycemia, dyslipidemia, blood pressure, and liver function is necessary for patients with bipolar affective disorder.
Blood concentrations of lithium and valproate, when taken by the patient, should be regularly monitored to ensure they are within the therapeutic range. In addition, renal and thyroid function testing is necessary because treatment with lithium is known to be associated with tubulointerstitial nephropathy, hypothyroidism, and nephrogenic diabetes insipidus. For patients receiving valproate, the hepatic function should be monitored, and, in women, cases of polycystic ovary disease are known with valproate therapy.
Bipolar 1 disorder usually has a poor prognosis. 50% of patients experience a second episode within two years of the first episode.
Poor prognosis is associated with:
Lithium prophylaxis improves prognosis in about 50% of patients. About 45% of patients have a chronic disorder. The mean number of episodes of mania is 9, and the range is 2-30. More episodes indicate a poorer prognosis.
As discussed above, patients with bipolar affective disorder are at higher risk for suicidal ideation and attempts, which lead to a poorer prognosis.
The bipolar affective disorder has a progressive course and has implications on the patient’s cognitive and functional domains, in addition to affecting their physical health. Although patients with bipolar disorder may have normal or even higher cognition before diagnosis in many cognitive and neuroimaging studies, bipolar disorder has been related to significant neurocognitive deficits through all mood states, including periods of remission. In addition to cognition and functioning, physical health is also affected profoundly in patients with bipolar disorder Incidence of obesity, cardiovascular disorders, and diabetes is higher and arise earlier in the life course compared with the general population. There are reports of increased mortality as well, with findings of one study which followed patients over a 30-year period showing that circulatory disorders and suicide are the main causes of death.
It is important to educate patients and families on the importance of medication compliance, signs of hypomania, and mania. One of the greatest challenges includes ongoing engagement with treatment as most patients experience multiple manic, hypomanic, or depressive episodes in their life, and this is often secondary to medication non-compliance. Patients are asked to engage with both therapists and psychopharmacologists regularly and even support groups. Often patients may relapse even when they are adherent to medications. Support and ongoing psychoeducation of both patients and families are crucial in ongoing treatment.
The bipolar affective disorder is a serious mental disorder that results in impairments in the functionality of daily life, leading to increased costs for both patients and society. It is a multifaceted disease, and a comprehensive biological, social, and psychological approach should be employed in its management. The diagnosis of bipolar affective disorder frequently poses a diagnostic challenge. These patients may exhibit a variety of signs and symptoms such as depression, hypomania, mania, irritability, insomnia resulting in psychological distress over a long period of time. It is not always easy to obtain the exact timeline and chronology of symptoms, which frequently results in misdiagnosis. While the mental status exam of the patient may point towards the diagnosis of bipolar affective disorder, it is usually difficult to obtain a proper history of the patient's symptoms in one clinical visit. It is important to engage the patient in an empathic way and develop a therapeutic alliance to facilitate better treatment results.
While a psychiatrist or nurse practitioner is almost always involved in the care of patients with bipolar affective disorder, it is important to obtain the input about the patient's behavior and symptoms from the interdisciplinary psychologists, activity therapists, nurses, nurse practitioners, physician assistants, pharmacists, behavioral health associates, and social workers especially in the inpatient unit and emergency services while taking care of the patient in these settings. Nurses are vital members of the interprofessional group as they monitor the patient's behavior, medication compliance, vital signs, and assist with psychoeducation of the patient and family. Psychopharmacologists are specialized in the field of psychotropic medications and called upon for complex medication management and education. To improve outcomes, an interdisciplinary approach is a mainstay in the treatment of patients with bipolar disorder. An interprofessional team that provides a holistic and integrated approach to patient care can help achieve the best possible outcomes. Once the patient is discharged to home, shelter, or supportive housing, consultation should be made with a social worker and community nurses who can monitor the patient and make referrals as needed.
|||Grande I,Berk M,Birmaher B,Vieta E, Bipolar disorder. Lancet (London, England). 2016 Apr 9; [PubMed PMID: 26388529]|
|||Whiteford HA,Ferrari AJ,Degenhardt L,Feigin V,Vos T, The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PloS one. 2015; [PubMed PMID: 25658103]|
|||Blanco C,Compton WM,Saha TD,Goldstein BI,Ruan WJ,Huang B,Grant BF, Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III. Journal of psychiatric research. 2017 Jan; [PubMed PMID: 27814503]|
|||Miklowitz DJ,Johnson SL, The psychopathology and treatment of bipolar disorder. Annual review of clinical psychology. 2006 [PubMed PMID: 17716069]|
|||McGuffin P,Rijsdijk F,Andrew M,Sham P,Katz R,Cardno A, The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Archives of general psychiatry. 2003 May [PubMed PMID: 12742871]|
|||Keener MT,Phillips ML, Neuroimaging in bipolar disorder: a critical review of current findings. Current psychiatry reports. 2007 Dec [PubMed PMID: 18221633]|
|||[PubMed PMID: 16946919]|
|||Bebbington P,Ramana R, The epidemiology of bipolar affective disorder. Social psychiatry and psychiatric epidemiology. 1995 Nov; [PubMed PMID: 8560330]|
|||Pini S,de Queiroz V,Pagnin D,Pezawas L,Angst J,Cassano GB,Wittchen HU, Prevalence and burden of bipolar disorders in European countries. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2005 Aug; [PubMed PMID: 15935623]|
|||Merikangas KR,Jin R,He JP,Kessler RC,Lee S,Sampson NA,Viana MC,Andrade LH,Hu C,Karam EG,Ladea M,Medina-Mora ME,Ono Y,Posada-Villa J,Sagar R,Wells JE,Zarkov Z, Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archives of general psychiatry. 2011 Mar; [PubMed PMID: 21383262]|
|||Tsuchiya KJ,Byrne M,Mortensen PB, Risk factors in relation to an emergence of bipolar disorder: a systematic review. Bipolar disorders. 2003 Aug; [PubMed PMID: 12895201]|
|||Kessing LV, Diagnostic subtypes of bipolar disorder in older versus younger adults. Bipolar disorders. 2006 Feb; [PubMed PMID: 16411981]|
|||Kroon JS,Wohlfarth TD,Dieleman J,Sutterland AL,Storosum JG,Denys D,de Haan L,Sturkenboom MC, Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar disorders. 2013 May; [PubMed PMID: 23531096]|
|||Kapczinski NS,Narvaez JC,Magalhães PV,Bücker J,Peuker AC,Loredo AC,Troiano F,Czepielewski L,Rosa A,Fries GR,Gama CS, Cognition and functioning in bipolar depression. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2016 Jul-Sep; [PubMed PMID: 26870909]|
|||Tondo L,Isacsson G,Baldessarini R, Suicidal behaviour in bipolar disorder: risk and prevention. CNS drugs. 2003; [PubMed PMID: 12751919]|
|||Pompili M,Gonda X,Serafini G,Innamorati M,Sher L,Amore M,Rihmer Z,Girardi P, Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar disorders. 2013 Aug; [PubMed PMID: 23755739]|
|||Gibbons RD,Hur K,Brown CH,Mann JJ, Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Archives of general psychiatry. 2009 Dec; [PubMed PMID: 19996040]|
|||Schaffer A,Isometsä ET,Tondo L,H Moreno D,Turecki G,Reis C,Cassidy F,Sinyor M,Azorin JM,Kessing LV,Ha K,Goldstein T,Weizman A,Beautrais A,Chou YH,Diazgranados N,Levitt AJ,Zarate CA Jr,Rihmer Z,Yatham LN, International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar disorders. 2015 Feb; [PubMed PMID: 25329791]|
|||McIntyre RS,Konarski JZ,Soczynska JK,Wilkins K,Panjwani G,Bouffard B,Bottas A,Kennedy SH, Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatric services (Washington, D.C.). 2006 Aug; [PubMed PMID: 16870965]|
|||Grande I,Fries GR,Kunz M,Kapczinski F, The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry investigation. 2010 Dec; [PubMed PMID: 21253407]|
|||Konopaske GT,Lange N,Coyle JT,Benes FM, Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA psychiatry. 2014 Dec 1; [PubMed PMID: 25271938]|
|||Berk M,Kapczinski F,Andreazza AC,Dean OM,Giorlando F,Maes M,Yücel M,Gama CS,Dodd S,Dean B,Magalhães PV,Amminger P,McGorry P,Malhi GS, Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and biobehavioral reviews. 2011 Jan; [PubMed PMID: 20934453]|
|||Berk L,Hallam KT,Colom F,Vieta E,Hasty M,Macneil C,Berk M, Enhancing medication adherence in patients with bipolar disorder. Human psychopharmacology. 2010 Jan; [PubMed PMID: 20041478]|
|||Grande I,Vieta E, Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? CNS drugs. 2015 Mar; [PubMed PMID: 25711483]|
|||Malhi GS,Tanious M,Berk M, Mania: diagnosis and treatment recommendations. Current psychiatry reports. 2012 Dec; [PubMed PMID: 22986995]|
|||Grande I,Hidalgo-Mazzei D,Nieto E,Mur M,Sàez C,Forcada I,Vieta E, Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study. European psychiatry : the journal of the Association of European Psychiatrists. 2015 Jun; [PubMed PMID: 25682181]|
|||Fornaro M,De Berardis D,Perna G,Solmi M,Veronese N,Orsolini L,Buonaguro EF,Iasevoli F,Köhler CA,Carvalho AF,de Bartolomeis A, Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed research international. 2017 [PubMed PMID: 28573138]|
|||Vieta E, Antidepressants in bipolar I disorder: never as monotherapy. The American journal of psychiatry. 2014 Oct; [PubMed PMID: 25272338]|
|||Schoeyen HK,Kessler U,Andreassen OA,Auestad BH,Bergsholm P,Malt UF,Morken G,Oedegaard KJ,Vaaler A, Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. The American journal of psychiatry. 2015 Jan; [PubMed PMID: 25219389]|
|||Vieta E,Langosch JM,Figueira ML,Souery D,Blasco-Colmenares E,Medina E,Moreno-Manzanaro M,Gonzalez MA,Bellivier F, Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). The international journal of neuropsychopharmacology. 2013 Sep; [PubMed PMID: 23663490]|
|||Colom F,Vieta E,Martínez A,Jorquera A,Gastó C, What is the role of psychotherapy in the treatment of bipolar disorder? Psychotherapy and psychosomatics. 1998; [PubMed PMID: 9491434]|
|||Colom F,Vieta E,Martinez-Aran A,Reinares M,Goikolea JM,Benabarre A,Torrent C,Comes M,Corbella B,Parramon G,Corominas J, A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of general psychiatry. 2003 Apr; [PubMed PMID: 12695318]|
|||Colom F,Vieta E,Sánchez-Moreno J,Palomino-Otiniano R,Reinares M,Goikolea JM,Benabarre A,Martínez-Arán A, Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. The British journal of psychiatry : the journal of mental science. 2009 Mar; [PubMed PMID: 19252157]|
|||Scott J,Paykel E,Morriss R,Bentall R,Kinderman P,Johnson T,Abbott R,Hayhurst H, Cognitive-behavioural therapy for bipolar disorder. The British journal of psychiatry : the journal of mental science. 2006 May; [PubMed PMID: 16648539]|
|||Frank E,Kupfer DJ,Wagner EF,McEachran AB,Cornes C, Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors. Archives of general psychiatry. 1991 Dec; [PubMed PMID: 1845438]|
|||Jensen AL,Iversen L,Høier R,Kristensen F,Henriksen P, Evaluation of an immunoradiometric assay for thyrotropin in serum and plasma samples of dogs with primary hypothyroidism. Journal of comparative pathology. 1996 Apr; [PubMed PMID: 8762591]|
|||Torrent C,Bonnin Cdel M,Martínez-Arán A,Valle J,Amann BL,González-Pinto A,Crespo JM,Ibáñez Á,Garcia-Portilla MP,Tabarés-Seisdedos R,Arango C,Colom F,Solé B,Pacchiarotti I,Rosa AR,Ayuso-Mateos JL,Anaya C,Fernández P,Landín-Romero R,Alonso-Lana S,Ortiz-Gil J,Segura B,Barbeito S,Vega P,Fernández M,Ugarte A,Subirà M,Cerrillo E,Custal N,Menchón JM,Saiz-Ruiz J,Rodao JM,Isella S,Alegría A,Al-Halabi S,Bobes J,Galván G,Saiz PA,Balanzá-Martínez V,Selva G,Fuentes-Durá I,Correa P,Mayoral M,Chiclana G,Merchan-Naranjo J,Rapado-Castro M,Salamero M,Vieta E, Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. The American journal of psychiatry. 2013 Aug; [PubMed PMID: 23511717]|
|||Solé B,Bonnin CM,Mayoral M,Amann BL,Torres I,González-Pinto A,Jimenez E,Crespo JM,Colom F,Tabarés-Seisdedos R,Reinares M,Ayuso-Mateos JL,Soria S,Garcia-Portilla MP,Ibañez Á,Vieta E,Martinez-Aran A,Torrent C, Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015 Feb; [PubMed PMID: 24906790]|
|||Ng F,Mammen OK,Wilting I,Sachs GS,Ferrier IN,Cassidy F,Beaulieu S,Yatham LN,Berk M, The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar disorders. 2009 Sep; [PubMed PMID: 19689501]|
|||Tiihonen J,Haukka J,Henriksson M,Cannon M,Kieseppä T,Laaksonen I,Sinivuo J,Lönnqvist J, Premorbid intellectual functioning in bipolar disorder and schizophrenia: results from a cohort study of male conscripts. The American journal of psychiatry. 2005 Oct; [PubMed PMID: 16199837]|
|||Pomarol-Clotet E,Alonso-Lana S,Moro N,Sarró S,Bonnin MC,Goikolea JM,Fernández-Corcuera P,Amann BL,Romaguera A,Vieta E,Blanch J,McKenna PJ,Salvador R, Brain functional changes across the different phases of bipolar disorder. The British journal of psychiatry : the journal of mental science. 2015 Feb; [PubMed PMID: 25497296]|
|||Martínez-Arán A,Vieta E,Reinares M,Colom F,Torrent C,Sánchez-Moreno J,Benabarre A,Goikolea JM,Comes M,Salamero M, Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. The American journal of psychiatry. 2004 Feb; [PubMed PMID: 14754775]|
|||Kilbourne AM,Cornelius JR,Han X,Pincus HA,Shad M,Salloum I,Conigliaro J,Haas GL, Burden of general medical conditions among individuals with bipolar disorder. Bipolar disorders. 2004 Oct; [PubMed PMID: 15383128]|
|||Fiedorowicz JG,Palagummi NM,Forman-Hoffman VL,Miller DD,Haynes WG, Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2008 Jul-Sep; [PubMed PMID: 18633739]|
|||Angst F,Stassen HH,Clayton PJ,Angst J, Mortality of patients with mood disorders: follow-up over 34-38 years. Journal of affective disorders. 2002 Apr; [PubMed PMID: 12063145]|